Retrospective Viability Study of the PETHEMA-POMCIDEX Clinical Practice Guidelines for the Treatment of Patients With Relapsed and Refractory Multiple Myeloma (RRMM)

CompletedOBSERVATIONAL
Enrollment

110

Participants

Timeline

Start Date

April 27, 2018

Primary Completion Date

July 14, 2020

Study Completion Date

July 14, 2020

Conditions
Relapsed and Refractory Multiple Myeloma
Trial Locations (27)

Unknown

Hospital de Sant Joan de Déu, Barcelona

Hospital Donostia-Donostia Ospitalea, Donostia / San Sebastian

Hospital Universitario Virgen de Las Nieves, Granada

Hospital General San Jorge - Huesca, Huesca

Hospital de Jaén, Jaén

Hospital Lucus Augusti, Lugo

Hospital Clínico San Carlos, Madrid

Hospital Del Tajo, Madrid

Hospital General Universitario Gregorio Marañón, Madrid

Hospital Ramón Y Cajal, Madrid

Hospital Universitario 12 de Octubre, Madrid

Hospital Universitario de La Princesa, Madrid

Hospital Universitario Infanta Leonor, Madrid

Complejo Hospitalario de Especialidades Virgen de La Victoria, Málaga

Hospital Universitario Virgen de La Arrixaca, Murcia

Hospital Central de Asturias, Oviedo

Hospital Universitari Son Espases, Palma de Mallorca

Complejo Hospitalario de Navarra, Pamplona

Hospital El Bierzo, Ponferrada

Hospital Universitario de Salamanca, Salamanca

Hospital Mutua Terrassa, Terrassa

Complejo Hospitalario de Toledo, Toledo

Hospital Arnau de Vilanova, Valencia

Hospital Universitario Dr. Peset Aleixandre, Valencia

Hospital Universitario La Fe, Valencia

HOSPITAL CLíNICO UNIVERSITARIO DE VALLADOLID, Valladolid

Hospital Txagorritxu, Vitoria-Gasteiz

All Listed Sponsors
lead

PETHEMA Foundation

OTHER

NCT03477643 - Retrospective Viability Study of the PETHEMA-POMCIDEX Clinical Practice Guidelines for the Treatment of Patients With Relapsed and Refractory Multiple Myeloma (RRMM) | Biotech Hunter | Biotech Hunter